Allurion Technologies Files S-1
Ticker: ALURW · Form: S-1 · Filed: May 31, 2024 · CIK: 1964979
| Field | Detail |
|---|---|
| Company | Allurion Technologies, INC. (ALURW) |
| Form Type | S-1 |
| Filed Date | May 31, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001, $1.51, $4.0 million, $28.7 million, $100.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1, restructuring, financial-reporting
Related Tickers: ALUR
TL;DR
Allurion Tech (ALUR) filed S-1, showing biz details post-restructuring. Watch for share adjustments.
AI Summary
Allurion Technologies, Inc. filed an S-1 form on May 31, 2024, detailing its financial status and business operations. The company, previously known as Allurion Technologies Holdings, Inc., is incorporated in Delaware and operates in the surgical and medical instruments sector. Its principal business address is in Natick, MA. The filing indicates a retrospective adjustment to common shares and per-share calculations due to a business combination.
Why It Matters
This S-1 filing provides crucial financial and operational details for investors and the public regarding Allurion Technologies, Inc.'s business and its recent corporate restructuring.
Risk Assessment
Risk Level: medium — As an S-1 filing, it represents a company preparing for significant financial events like an IPO or major debt offering, which inherently carries market and operational risks.
Key Players & Entities
- ALLURION TECHNOLOGIES, INC. (company) — Filer name
- ALLURION TECHNOLOGIES HOLDINGS, INC. (company) — Former company name
- May 31, 2024 (date) — Filing date
- Natick, MA (location) — Business address
- Delaware (location) — State of incorporation
FAQ
What is the primary business of Allurion Technologies, Inc.?
Allurion Technologies, Inc. operates in the sector of Surgical & Medical Instruments & Apparatus, as indicated by its SIC code [3841].
When was the company's name changed?
The company's name was changed from Allurion Technologies Holdings, Inc. on February 7, 2023.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the business address of Allurion Technologies, Inc.?
The business address is 11 Huron Dr Ste 200, Natick, MA 01760.
What adjustment was made to the company's share calculations?
The weighted-average common shares and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization.
Filing Stats: 4,680 words · 19 min read · ~16 pages · Grade level 14.7 · Accepted 2024-05-31 17:31:22
Key Financial Figures
- $0.0001 — 1,900 shares of common stock, par value $0.0001 per share ("common stock"), of Allurion
- $1.51 — ommon stock as reported on the NYSE was $1.51 per share. Sales of a substantial num
- $4.0 million — op Purchasers purchased an aggregate of $4.0 million of the HVL Bridge Note at the Backstop
- $28.7 million — Directors. " Bridge Notes " refers to $28.7 million aggregate principal amount of convertib
- $100.0 million — agreed to purchase from Allurion up to $100.0 million of freely tradable shares of common sto
- $11 — A Common Stock at an exercise price of $11.50, subject to adjustment as set forth
- $60 million — refers to the term loan in an amount of $60 million provided by Fortress to Legacy Allurion
- $13 million — VL Bridge Note " refers to that certain $13 million Bridge Note sold to HVL on February 15,
Filing Documents
- d831153ds1.htm (S-1) — 4229KB
- d831153dex51.htm (EX-5.1) — 7KB
- d831153dex231.htm (EX-23.1) — 1KB
- d831153dexfilingfees.htm (EX-FILING FEES) — 18KB
- g831153g0531063638603.jpg (GRAPHIC) — 3KB
- g831153g30a01.jpg (GRAPHIC) — 37KB
- g831153g30a02.jpg (GRAPHIC) — 116KB
- g831153g30a03.jpg (GRAPHIC) — 63KB
- g831153g30a04.jpg (GRAPHIC) — 141KB
- g831153g30a05.jpg (GRAPHIC) — 158KB
- g831153g30a06.jpg (GRAPHIC) — 89KB
- g831153g30a07.jpg (GRAPHIC) — 165KB
- g831153g30a08.jpg (GRAPHIC) — 43KB
- 0001193125-24-151994.txt ( ) — 19084KB
- alur-20240331.xsd (EX-101.SCH) — 113KB
- alur-20240331_cal.xml (EX-101.CAL) — 81KB
- alur-20240331_def.xml (EX-101.DEF) — 543KB
- alur-20240331_lab.xml (EX-101.LAB) — 798KB
- alur-20240331_pre.xml (EX-101.PRE) — 712KB
- d831153ds1_htm.xml (XML) — 3408KB
RISK FACTORS
RISK FACTORS 22 PRIVATE PLACEMENT OF NOTES 77
USE OF PROCEEDS
USE OF PROCEEDS 79 DETERMINATION OF OFFERING PRICE 80 MARKET PRICE AND DIVIDEND INFORMATION 81
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF ALLURION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF ALLURION 108 MANAGEMENT 130
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 141 DIRECTOR COMPENSATION 146 PRINCIPAL STOCKHOLDERS 148 SELLING SECURITYHOLDER 150 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 153
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 158 SECURITIES ACT RESTRICTIONS ON RESALE OF OUR SECURITIES 169 PLAN OF DISTRIBUTION (CONFLICTS OF INTEREST) 170 LEGAL MATTERS 172 EXPERTS 172 WHERE YOU CAN FIND MORE INFORMATION 172 INDEX TO FINANCIAL STATEMENTS ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES F-1 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (dollars in thousands) F-3 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (dollars in thousands, except per share amounts) F-4 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (dollars in thousands) F-5 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (dollars in thousands) F-6 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (dollars in thousands, except per share amounts) . F-8 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC whereby the selling securityholder may, from time to time, sell the securities offered by it described in this prospectus. We will not receive any proceeds from the sale by such selling securityholder of the securities offered by it described in this prospectus. Neither we nor the selling securityholder has authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the selling securityholder takes responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the selling securityholder will make an offer to sell these securities in any jurisdiction where such offer or sale is not permitted. No